GTC antithrombin ATryn assigned priority review
This article was originally published in Pharmaceutical Approvals Monthly
FDA assigns priority review to GTC Biotherapeutics' antithrombin ATryn, firm says Sept. 4. The BLA's target user fee date is Feb. 7, 2009. GTC filed the final portion of the rolling BLA for ATryn Aug. 7 for prophylactic treatment of deep vein thrombosis and other thromboembolisms in patients with hereditary antithrombin deficiency who are undergoing high risk surgical and childbirth procedures. Ovation Pharmaceuticals has the license for development and marketing of ATryn in the U.S. The drug is already approved for antithrombin hereditary deficiency in Europe, where a Phase II trial is underway testing ATryn in disseminated intravascular coagulation associated with severe sepsis. Top-line results are due in the second half of next year
You may also be interested in...
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.